Eli Lilly: buys exclusive rights for non-opioid painkiller

(CercleFinance.com) - US drugmaker Eli Lilly has bought the exclusive rights for non-opioid, non-addictive therapeutics for the treatment of chronic pain, the group said on Tuesday.


Under the terms of the agreement, Lilly will make Centrexion, a late clinical-stage biopharmaceutical company, an upfront payment of 47.5 million dollars.

Centrexion may be eligible for up to 575 million dollars in potential development and regulatory milestones.

If the painkiller is successfully marketed, Centrexion would be eligible for up to 375 million dollars in potential sales milestones and royalties, Lilly said.

The CNTX-0290 compound is currently being studied in Phase 1 clinical testing as a potential non-opioid treatment for chronic pain conditions.

Copyright (c) 2019 CercleFinance.com. All rights reserved.